Recombinant Polypeptide Conjugation for Safe Anti-Inflammatory Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases are largely empirical and have limitations due to safety concerns, with complex mechanisms not fully understood, and existing anti-inflammatory drugs like ibuprofen and dexamethasone have human safety issues, while mussel adhesive proteins show promise but lack anti-inflammatory effects.
Innovation Solution
A recombinant polypeptide is developed by conjugating functional peptides, such as antimicrobial peptides, to biocompatible mussel adhesive proteins, creating a composition that can be used in pharmaceutical and cosmetic applications to suppress inflammatory cytokines and tumor necrosis factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-inflammatory drugs (ibuprofen, dexamethasone) are used, then inflammation is suppressed, but human safety is compromised
Solution Approach 1:
The patent uses mussel adhesive protein as an intermediary carrier that conjugates with functional peptides (such as antimicrobial peptides) to create a recombinant polypeptide. This intermediary structure allows the functional peptides to exert anti-inflammatory effects while the mussel adhesive protein provides biocompatibility and safety, resolving the contradiction between effective inflammation suppression and human safety.
Solution Approach 2:
The patent creates a composite recombinant polypeptide by conjugating functional peptides to mussel adhesive protein. This composite structure combines the anti-inflammatory properties of functional peptides with the biocompatible and safe characteristics of mussel adhesive protein, achieving both effective treatment and safety simultaneously.
2Object-affected harmful factors
If mussel adhesive protein is used as a biocompatible material, then safety is improved, but anti-inflammatory effect is insufficient
Solution Approach 1:
The patent merges mussel adhesive protein with functional peptides (such as antimicrobial peptides) through conjugation. This merging allows the resulting recombinant polypeptide to simultaneously possess the biocompatibility and safety of mussel adhesive protein and the anti-inflammatory effect of functional peptides, resolving the insufficiency of anti-inflammatory activity in pure mussel adhesive protein.
Solution Approach 2:
The recombinant polypeptide created by conjugating functional peptides to mussel adhesive protein achieves multi-functionality: it provides biocompatibility and safety from the mussel adhesive protein component while delivering anti-inflammatory effects from the functional peptide component, making it universally applicable for safe and effective anti-inflammatory treatment.
3Reliability
If functional peptide is conjugated to biocompatible polypeptide, then anti-inflammatory effect is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent uses recombinant DNA technology to create a copy of the desired recombinant polypeptide sequence. By synthesizing the gene encoding the functional peptide-mussel adhesive protein conjugate and expressing it in host cells, the complex conjugation process is simplified into a standardized molecular cloning workflow, reducing manufacturing complexity while maintaining enhanced anti-inflammatory effects.
Data Source
AI summary
The present invention relates to a composition for the suppression or amelioration of inflammatory diseases, comprising a recombinant polypeptide in which a functional peptide is conjugated to a biocompatible polypeptide. The composition of the present invention is not only safe for the human body, but can also be widely applied to the suppression of inflammation by inhibiting cytokines and tumor necrosis factors that cause early inflammation. Thus, the composition can be used in fields such as medicines, medical products, cosmetics, and daily necessities, to suppress inflammation, and can also be used in the development of additional new drugs.